Key result
Metabolic inhibition test enables serologic diagnosis of group B Coxsackie virus in ~84% of cases.
Why the study?
Can a metabolic inhibition test effectively determine antibodies to group B Coxsackie viruses?
Can a metabolic inhibition test effectively determine antibodies to group B Coxsackie viruses?
A metabolic inhibition test can successfully provide serologic diagnosis for group B Coxsackie virus infections in up to 84% of cases.
Answers are grounded in this paper and cite their sources.
May aid Coxsackie B serologic diagnosis; leaves open need for prospective clinical validation.
A metabolic inhibition test for detection of antibodies to 5 group B Coxsackie virus serotypes has been described. A serologic diagnosis could be made in as high as 84% of cases. Persons possessing neutralizing antibodies from previous group B Coxsackie virus infections frequently showed heterologous as well as homologous antibody increases.
No takes yet. Share an insight, caveat, or question.
Rogers et al. (1958) studied this question. The metabolic inhibition test for detecting antibodies to five group B Coxsackie virus serotypes enabled serologic diagnosis in up to 84% of cases.
Synapse has enriched 10 related papers. Consider them for comparative context: